A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

BACKGROUND: Targeted therapies in HER2-positive metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance. HER2 is an acutely sensitive Heat Shock Protein 90 (HSP90) client and HSP90 inhibition can overcome trastuzumab resistance. Preclinical data sugg...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res
Main Authors: Jhaveri, Komal, Wang, Rui, Teplinsky, Eleonora, Chandarlapaty, Sarat, Solit, David, Cadoo, Karen, Speyer, James, D’Andrea, Gabriella, Adams, Sylvia, Patil, Sujata, Haque, Sofia, O’Neill, Tara, Friedman, Kent, Esteva, Francisco J., Hudis, Clifford, Modi, Shanu
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2017
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5540198/
https://ncbi.nlm.nih.gov/pubmed/28764748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-017-0879-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares